Read our latest updates & insights

Selexis SA announces it has executed two commercial licence agreements with Turgut Pharmaceuticals for the development of biosimilar antibodies. This expansion of the partnership between the two companies aims to develop a biosimilar for the treatment of metastatic HER2-pos...

Samsung Bioepis partners with C-Bridge to commercialise biosimilars in China. Under the deal, C-Bridge will develop a new company, AffaMed Therapeutics to launch candidates such as ranibizumab, eculizumab and trastuzumab biosimilars.

Sandoz files suit against Amgen, seeking DJ of non-infringement and invalidity. This comes as Sandoz awaits FDA decision on its pegfilgrastim biosimilar, with Sandoz hoping to block any preliminary injunction motions from Amgen.

China’s National Medical Products Administration approves first rituximab biosimilar, Hanlikon®.

Alteogen announces new drug application to the Ministry of Food and Drug Safety for aflibercept biosimilar, ALT-L9.

Biosana announces approval for Phase 1 trials of biosimilar omalizumab, with results expected in the fourth quarter of 2019.

Pfizer announces EU approval for Zirabev®, biosimilar BmAb.

In its final appraisal of pertuzumab, the National Institute for Health and Care Excellence (NICE) has recommended it for the treatment of lympth node-positive disease. The final appraisal comes following the promise of a large discount offered by Roche.

Samsung Bioepis announces partnership with C-Bridge to commercialise biosimilars in China. Under the deal, C-Bridge will develop a new company, AffaMed Therapeutics to launch candidates such as ranibizumab, eculizumab and trastuzumab biosimilars.

Mundipharma launches pegfilgrastim biosimilar, Pelmeg®, in Europe. Pelmeg® was developed by Cinfa Biotech, and is the fourth biosimilar commercialised by Mundipharma.